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Summary. Archival biopsy specimens from transitional 
cell bladder cancers (n=88) were analysed immuno- 
histochemically for the expression of the retinoblastoma 
(Rb) gene protein, p53, mdm2, c-erbB-2, HLA-DR 
antigen and proliferation indices. An altered nuclear 
expression of Rb, p53 and mdm2 was observed in 
55.2%, 33.3% and 18.2% of tumors respectively. 
Cytoplasmic membrane immunoreactivity (>25% tumor 
cells) for c-erbB-2 was detected in 14.1% of tumors and 
aberrant HLA-DR antigen cytoplasmic staining (>5% of 
tumor cells) in 22.2% of the cases. 
P53 overexpression was associated with higher 
tumor grade and stage. Aberrant HLA-DR antigen 
expression and PCNA were also correlated with the 
grade of differentiation and tumor stage. MIBl was 
statistically correlated with stage. pRb scores and HLA- 
DR antigen expression were correlated with proliferation 
activity as determined by PCNA and M I B l  
immunostaining. p53 protein was also strongly 
correlated with the proliferation index PCNA. A strong 
correlation between PCNA and MIBl (pc0.0001) was 
also found. In addition a statistically positive correlation 
between p53 and HLA-DR antigen expression was 
observed. Our data show that, although pRb and p53 
protein expressions are not associated between them, 
they may contribute to the growth fraction of the bladder 
cancer. In addition, p53 and HLA-DR antigen expression 
could be indicators of aggressive behavior of bladder 
cancer. 
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Introduction 
There is increasing evidence that the alteration of 
tumor suppressor genes may play a role in the initiation 
and progression of human tumors. Of these, the best 
characterized are the retinoblastoma (Rb) and p53 tumor 
suppressor genes. Rb and p53 share some characteristics: 
both code for nuclear phosphoproteins present in normal 
cells and are thought to be involved in cell cycle control 
and in the negative regulation of cell growth. Alterations 
of the Rb gene have been observed in several epithelia1 
tumors suggest ing that structural abnormalities,  
including mutations andlor deletions of the Rb gene, 
may result in the inactivation of tumor suppressor 
protein and may be involved in tumorigenesis (Harbour 
et al., 1988; Lee et al., 1988; Goodrich et al., 1991; Lin 
et al., 1991; Weinberg, 1991; Cordon-Cardo, 1995; 
Haas-Kogan et al., 1995; Jares et al., 1997). It has been 
shown that altered pRb patterns, may become an 
important prognostic variable in bladder cancer (Cairns 
et al., 1991; Cordon-Cardo et al., 1992; Logothetis et al., 
1992; Lipponen and Liukkonen 1995; Wright et al., 
1995; Cordon-Cardo et al., 1997; Cordon-Cardo and 
Reuter, 1997). Mutations of the p53 gene are commonly 
found in bladder cancer and are associated with an 
aggressive clinical course (Lipponen, 1993; Moch et al., 
1993, 1994; Soini et al., 1993; Wright et al., 1995; 
Wagner et al., 1995; Skopelitou et al., 1997). More 
recently, a cellular proto-oncogene product, the mdm2 
has been shown to bind to p53 and acts as a negative 
regulator, inhibiting its transcriptional transactivation 
activity. It has been shown that aberrant mdm2 and p53 
phenotypes may be important diagnostic markers in 
patients affected by bladder cancer (Lianes et al., 1994). 
C-erbB-2 amplification and over-expression may 
provide a useful molecular marker in transitional cell 
carcinoma of the bladder and merits further investigation 
as a potential prognostic indicator (Berner et al., 1993; 
Moch et al., 1993, 1994; Gorgoulis at al., 1995; Wagner 
et al., 1995). In addition, previous studies showed that 






